A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)
Latest Information Update: 21 Nov 2023
At a glance
- Drugs Olaparib (Primary) ; Abiraterone acetate; Enzalutamide; Prednisolone; Prednisone
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROfound
- Sponsors AstraZeneca
- 14 Nov 2023 Results of exploratory post hoc analysis of the subgroup of patients with mCRPC with BRCA alterations published in the Journal of Clinical Oncology.
- 21 Oct 2023 This trial has been completed in Spain according European Clinical Trials Database record.
- 09 Mar 2023 Status changed from active, no longer recruiting to completed.